EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics announces its unaudited interim results for the six months ended 30 June 2020.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its interim results for the six months ended 30 June 2020 on Monday 14 September 2020.
US$5m funding into Trellus Health to transform care for complex chronic conditions
EKF Diagnostics announces that it has received an initial order worth £3m from a partner from the private sector to supply PrimeStore MTM
EKF Diagnostics provides the following trading update for the six months ended 30 June 2020 and confirmation that, since the 15 May 2020 update
Further increase in expected orders for PrimeStore MTM sample collection devices Orders received for the two months ending July totalling $9.4m
EKF Diagnostics Holdings plc announces that it has issued and allotted 500,000 ordinary shares of one pence each in the share capital of the Company following an exercise of options on 5 May 2020.